Literature DB >> 9661029

Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model.

G Schmuck1, A Schürmann, G Schlüter.   

Abstract

Fluoroquinolones have been reported to induce central nervous system side effects, including seizures and psychiatric events. Although relatively rare in patients up to now, the proconvulsant activity depends on the chemical structure and might be a critical endpoint of some new representatives of this valuable class of antimicrobials. The electrophysiological determination of field potentials in the CA1 region of the rat hippocampus slice allowed an assessment of the excitatory potential of fluoroquinolones and might be predictive for their neurotoxic potency in vivo. An optimization of this method and its extension to other fluoroquinolones resulted in a defined rank order. Well-known already-marketed quinolones as well as some fluoroquinolones under evaluation and development were used. The dose range tested was between 0.5 and 4 mumol/liter, which was comparable to the therapeutic concentration in the brain. All tested compounds increased the population spike amplitude in a concentration-dependent manner, and the resulting excitatory potency was highly dependent on the chemical structure, with compounds ranging from least to most excitatory as follows: ofloxacin, ciprofloxacin, nalidixic acid, moxifloxacin, BAY x 8843, [corrected] fleroxacin, lomefloxacin, enoxacin, clinafloxacin (much more excitatory than enoxacin), tosufloxacin, trovafloxacin, BAY 15-7828, and BAY x 9181 (much more excitatory than BAY 15-7828). The proposed hippocampus slice model not only is suitable for giving valuable alerts as to convulsive potential during candidate selection but also enables mechanistic investigations. These investigations pointed to the N-methyl-D-aspartate receptor as the probable target of the fluoroquinolone effects.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9661029      PMCID: PMC105691     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  Antagonism of GABAA receptors by 4-quinolones.

Authors:  R F Halliwell; P G Davey; J J Lambert
Journal:  J Antimicrob Chemother       Date:  1993-04       Impact factor: 5.790

2.  Electrical activities in thin sections from the mammalian brain maintained in chemically-defined media in vitro.

Authors:  C Yamamoto; H McIlwain
Journal:  J Neurochem       Date:  1966-12       Impact factor: 5.372

3.  In vitro modulation of hippocampal pyramidal cell response by quinolones: effects of HA 966 and gamma-hydroxybutyric acid.

Authors:  W Dimpfel; A Dalhoff; E von Keutz
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

4.  Attenuated inhibition by levofloxacin, l-isomer of ofloxacin, on GABA response in the dissociated rat hippocampal neurons.

Authors:  T Imanishi; K Akahane; N Akaike
Journal:  Neurosci Lett       Date:  1995-06-30       Impact factor: 3.046

5.  Magnesium gates glutamate-activated channels in mouse central neurones.

Authors:  L Nowak; P Bregestovski; P Ascher; A Herbet; A Prochiantz
Journal:  Nature       Date:  1984 Feb 2-8       Impact factor: 49.962

Review 6.  Impact of chemical structure on quinolone potency, spectrum and side effects.

Authors:  A Percival
Journal:  J Antimicrob Chemother       Date:  1991-12       Impact factor: 5.790

7.  In vitro and in vivo characterization of the NMDA receptor-linked strychnine-insensitive glycine site.

Authors:  B W Peeters; P M Vanderheyden
Journal:  Epilepsy Res       Date:  1992-07       Impact factor: 3.045

8.  Glycine-induced CA1 excitotoxicity in the rat hippocampal slice.

Authors:  R A Wallis; K L Panizzon; J P Nolan
Journal:  Brain Res       Date:  1994-11-21       Impact factor: 3.252

9.  Effects of some quinolones on imipenem-induced seizures in DBA/2 mice.

Authors:  A De Sarro; D Ammendola; G De Sarro
Journal:  Gen Pharmacol       Date:  1994-03

10.  Inhibitory effects of quinolone antibacterial agents on gamma-aminobutyric acid binding to receptor sites in rat brain membranes.

Authors:  A Tsuji; H Sato; Y Kume; I Tamai; E Okezaki; O Nagata; H Kato
Journal:  Antimicrob Agents Chemother       Date:  1988-02       Impact factor: 5.191

View more
  23 in total

Review 1.  Potential interactions of the extended-spectrum fluoroquinolones with the CNS.

Authors:  H Lode
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

Review 2.  Safety considerations of fluoroquinolones in the elderly: an update.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

Review 3.  Safety profile of the fluoroquinolones: focus on levofloxacin.

Authors:  Hans H Liu
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

Review 4.  Moxifloxacin.

Authors:  J A Balfour; L R Wiseman
Journal:  Drugs       Date:  1999-03       Impact factor: 9.546

Review 5.  Toxicity of quinolones.

Authors:  R Stahlmann; H Lode
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 6.  Comparative tolerability of the newer fluoroquinolone antibacterials.

Authors:  P Ball; L Mandell; Y Niki; G Tillotson
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 7.  Fluoroquinolones in the elderly: safety considerations.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  A seizure attributed to ofloxacine in a woman undergoing detoxification for alcohol dependence.

Authors:  Pierre Lahmek; Laurent Michel; Nadine Meunier; Henri-Jean Aubin
Journal:  Case Rep Med       Date:  2010-01-24

9.  Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy.

Authors:  Federico Pea; Federica Pavan; Ennio Nascimben; Claudio Benetton; Pier Giorgio Scotton; Alberto Vaglia; Mario Furlanut
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

Review 10.  Seizures associated with levofloxacin: case presentation and literature review.

Authors:  Alfredo Bellon; Gonzalo Perez-Garcia; John H Coverdale; Ranjit C Chacko
Journal:  Eur J Clin Pharmacol       Date:  2009-08-26       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.